Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 7, Issue 10 (2018)

Blood biochemical profile following administration of erlotinib, meloxicam and metformin alone and in combination in SCID mice

Author(s):
Satish D Patel, Urvesh D Patel, Kamlesh A Sadariya, Aswin M Thaker and Shailesh K Bhavsar
Abstract:
The study was carried out to evaluate blood biochemical profile following administration of erlotinib, meloxicam and metformin alone and in combination in SCID mice. The mean value of WBC of animal group treated by erlotinib with metformin was significantly increased in comparison to tumor control group. The neutrophil % of tumor control and all treatment groups was considerably high in comparison to normal control, whereas the lymphocyte % and eosinophil % count were decreased in tumor control and treatment group in comparison to normal control. The monocyte % count in animal group treated by metformin alone and in combination with erlotinib was significantly higher than tumor control group. The mean value of creatine kinase (CK) was significantly decreased in animal group treated with meloxicam in comparison to tumor control group. Whereas, the mean value of CK and blood urea nitrogen (BUN) of animal group treated with erlotinib with metformin was significantly increased in comparison to tumor control group. Raised level of BUN in present study might be due to additive damaging effect of metformin and erlotinib on kidney. The mean values of AST, ALT, TB and acid phosphatase of tumor control group were considerably high than normal control group. The mean values of ALP, total bilirubin, creatinine, and acid phosphatase did not alter. In conclusion, administration of erlotinib, meloxicam and metformin in combination alter blood biochemical profile in SCID mice.
Pages: 712-715  |  461 Views  39 Downloads


The Pharma Innovation Journal
How to cite this article:
Satish D Patel, Urvesh D Patel, Kamlesh A Sadariya, Aswin M Thaker, Shailesh K Bhavsar. Blood biochemical profile following administration of erlotinib, meloxicam and metformin alone and in combination in SCID mice. Pharma Innovation 2018;7(10):712-715.
Important Publications Links
The Pharma Innovation Journal

The Pharma Innovation Journal


Call for book chapter